Recruiting

Loargys

Sponsor:

Immedica Pharma US Inc

Code:

NCT07573059

Conditions

ARG1 Deficiency

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Loargys Arginine Test System

Study Details

Brief summary:

Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life.

Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine levels.

Because Loargys continues to break down arginine even after a blood sample has been taken, to ensure accurate results, a special substance (called nor-NOHA) is added to the blood collection tubes to stop this process after the sample is taken. The arginine levels are then measured using a standard laboratory test.

The Loargys Arginine Test System used in this study includes both the special blood collection tubes and the laboratory test used to measure arginine.

The purpose of this study is to evaluate the safety of this test system when used to measure arginine levels in patients receiving Loargys.

Conditions

ARG1 Deficiency

Study ID

NCT07573059

Start date

Apr 17, 2026

Status verified date

May, 2026

Completion date

Jul 15, 2027

Anticipated

Primary completion date

Jul 15, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant receiving treatment with commercialized Loargys for ARG1-D
  • Participant is willing to sign the Informed Consent Form

Exclusion Criteria:

  • None

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

other: Loargys Arginine Test System

Interventions

Loargys Arginine Test System

Loargys Arginine Test System

Primary outcome measure

  • Incidence of AEs related to the Loargys Arginine Test System [ Time Frame: Through study completion, up to 21 months ]

Central Contacts and Locations

Central contacts

Head of Global Integrated Evidence Generation

+46(0)853339500clinical@immedica.com

Locations

Rare Disease Research

Recruiting

Atlanta, Georgia, United States, 303029

Contacts

More Information

Sponsor

Immedica Pharma US Inc

Last update posted

May 7, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Immedica Pharma US Inc on 2026-05-07.